Modified Progressive Supranuclear Palsy Rating Scale (mPSPRS)
Permission is required for each single use of the MDS Clinical Outcome Assessments.
The Progressive Supranuclear Palsy Rating Scale (PSPRS) is a prospectively validated physician-rated measure of disease severity for progressive supranuclear palsy. The modified PSPRS (mPSPRS) is a condensed modified version of the scale focusing on meaningful disease milestones. The modified scale retained 14 items (yielding 0-2 points each, higher scores indicating higher disability). The items were rated as functionally relevant to disease milestones with comparable severity. The modified scale was sensitive to change over 6- and 12-months, and of similar power for clinical trials of disease-modifying therapy as the original scale (achieving 80% power for 2 sample t-test to detect a 50% slowing, with N=41 and 25% slowing with N=159 at 12-months). The mPSPRS serves as clinimetrically sound scale to monitor disease progression in clinical trials and routine.
Authors: Marie-Therese Grötsch, Gesine Respondek MD, Carlo Colosimo MD, Yaroslau Compta MD, Jean Christophe Corvol MD, PhDJoaquim Ferreira MD, Meret Koroni Huber MD, Martin Klietz MD, Lea F.M. Krey MD, Johannes Levin MD, Milica Jecmenica-Lukic MD, Daniel Macías-García MD, Wassilios G. Meissner MD, PhD, Pablo Mir MD, Huw Morris MD, Christer Nilsson MDa, James B. Rowe MD, PhD, Klaus Seppi MD, Maria Stamelou MD, PhD, John C. van Swieten MD, Gregor Wenning MD, PhD, Teodoro Del Ser MD, Lawrence I. Golbe MD, Günter U. Höglinger MD
Original Publication │ View the Scale (PDF) Permission required for use
- Acronym: mPSPRS
- Year Published: 2021
- Scale Last Updated: No updates since publication
- Assessment Type: Physician-rated clinical history and examination
- Estimated Time to Complete: 10 minutes
- No translations available
Eletronic builds: REDCap
To request permission to use this Rating Scale, please fill out a Permission Request Form.
